MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

被引：0

作者：

Kull, M. ^{[1
]}

Grosicki, S. ^{[2
]}

Yeh, S. -P. ^{[3
]}

Huang, J. S. Y. ^{[4
]}

Byun, J. M. ^{[5
]}

DiRienzo, C. ^{[6
]}

Viqueira, A. ^{[7
]}

机构：

[1] Univ Hosp Ulm, Dept Hematol, Ulm, Germany

[2] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[3] China Med Univ Hosp, Taichung, Taiwan

[4] Taiwan Univ Hosp, Taipei, Taiwan

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Pfizer Inc, New York, NY USA

[7] Pfizer SLU, Madrid, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1105

引用

页码：314 / 314

页数：1

共 50 条

[21] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
Kohmei Kubo
Mitsuo Hori
Kensuke Ohta
Hiroshi Handa
Kiyohiko Hatake
Morio Matsumoto
Shotaro Hagiwara
Kazuteru Ohashi
Chiaki Nakaseko
Kenshi Suzuki
Shigeki Ito
Gen Kinoshita
Suresh G. Shelat
Masafumi Miyoshi
Naoki Takezako
International Journal of Hematology, 2020, 111 : 65 - 74
[22] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
Kubo, Kohmei
Hori, Mitsuo
Ohta, Kensuke
Handa, Hiroshi
Hatake, Kiyohiko
Matsumoto, Morio
Hagiwara, Shotaro
Ohashi, Kazuteru
Nakaseko, Chiaki
Suzuki, Kenshi
Ito, Shigeki
Kinoshita, Gen
Shelat, Suresh G.
Miyoshi, Masafumi
Takezako, Naoki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 65 - 74
[23] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Ajay K. Nooka
Jonathan L. Kaufman
Cesar Rodriguez
Andrzej Jakubowiak
Yvonne Efebera
Brandi Reeves
Tanya Wildes
Sarah A. Holstein
Larry D. Anderson
Ashraf Badros
Leyla Shune
Ajai Chari
Huiling Pei
Annelore Cortoos
Sharmila Patel
J. Blake Bartlett
Jessica Vermeulen
Thomas S. Lin
Paul G. Richardson
Peter Voorhees
Blood Cancer Journal, 12
[24] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
BLOOD CANCER JOURNAL, 2022, 12 (04)
[25] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
Moustafa, Muhamad Alhaj
Parrondo, Ricardo
Abdulazeez, Mays F.
Roy, Vivek
Sher, Taimur
Alegria, Victoria R.
Warsame, Rahma M.
Larsen, Jeremy
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Kapoor, Prashant
Fonseca, Rafael
Buadi, Francis K.
Dingli, David
Hayman, Suzanne R.
Reeder, Craig B.
Agrawal, Arshi
Chanan-Khan, Asher A.
Ailawadhi, Sikander
BLOOD, 2020, 136
[26] MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma
Kortuem, M.
Manteca, Mateos M. V.
Grosicki, S.
Kim, K.
Negre, E.
Vandendries, E.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 182 - 182
[27] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Gay, Francesca
Musto, Pellegrino
Rota-Scalabrini, Delia
Bertamini, Luca
Belotti, Angelo
Galli, Monica
Offidani, Massimo
Zamagni, Elena
Ledda, Antonio
Grasso, Mariella
Ballanti, Stelvio
Spadano, Antonio
Cea, Michele
Patriarca, Francesca
D'Agostino, Mattia
Capra, Andrea
Giuliani, Nicola
de Fabritiis, Paolo
Aquino, Sara
Palmas, Angelo
Gamberi, Barbara
Zambello, Renato
Petrucci, Maria Teresa
Corradini, Paolo
Cavo, Michele
Boccadoro, Mario
LANCET ONCOLOGY, 2021, 22 (12): : 1705 - 1720
[28] Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
Narsipur, Nihal
Bulla, Sabrina
Yoo, Connie
Do, Brenda
Tran, Kyle
Gu, Dian
Zhong, Lixian
Wilson, Leslie
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12): : 1691 - 1702
[29] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Bahlis, Nizar J.
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Krevvata, Maria
Chiu, Christopher
Qin, Xiang
Okonkwo, Linda
Trivedi, Sonali
Ukropec, Jon
Qi, Ming
San-Miguel, Jesus
LEUKEMIA, 2020, 34 (07) : 1875 - 1884
[30] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis
Meletios A. Dimopoulos
Darrell J. White
Lotfi Benboubker
Gordon Cook
Merav Leiba
P. Joy Ho
Kihyun Kim
Naoki Takezako
Philippe Moreau
Jonathan L. Kaufman
Maria Krevvata
Christopher Chiu
Xiang Qin
Linda Okonkwo
Sonali Trivedi
Jon Ukropec
Ming Qi
Jesus San-Miguel
Leukemia, 2020, 34 : 1875 - 1884

← 1 2 3 4 5 →